MetaCap

Edesa Biotech (EDSA) vs NanoViricides (NNVC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Edesa Biotech (EDSA) has outperformed NanoViricides (NNVC) over the past year, gaining 17.6% versus a loss of 10.2%. Over five years, NNVC leads with a -76.5% price change compared with -95.6% for EDSA. NanoViricides is the larger company by market cap ($29.1 million vs $27.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EDSA+17.65%NNVC-10.24%
+1027%+461%-104%
Nov 21, 20251 yearNov 20, 2026
EDSA-95.72%NNVC-75.16%
+11%-46%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EDSA versus NNVC key metrics
MetricEDSANNVC
Share price$2.00$1.14
Market cap$27.02M$29.13M
1-day change-8.05%-2.56%
YTD return+40.85%+0.88%
1-year return+17.65%-10.24%
5-year return-95.63%-76.54%
EPS (TTM)$-1.72$-0.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-7.19M$-8.22M
52-week high$20.32$1.93
52-week low$0.72$0.85
Distance from 52-week high-90.16%-40.93%
Analyst consensusnonestrong_buy
Avg. price target upside+716.50%+426.32%
Average volume1.45M356.86K
Shares outstanding13.51M25.55M
Employees177
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EDSA has outperformed NNVC by 27.9 percentage points over the past year.

About Edesa Biotech

EDSA stock →

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About NanoViricides

NNVC stock →

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

EDSA vs NNVC FAQ

Which is bigger, Edesa Biotech or NanoViricides?

NanoViricides (NNVC) is larger, with a market capitalization of $29.13M compared with $27.02M for Edesa Biotech (EDSA).

Which stock has performed better over the past year, EDSA or NNVC?

EDSA returned +17.65% over the past 12 months, compared with -10.24% for NNVC (price return, excluding dividends). Past performance does not predict future results.

Are Edesa Biotech and NanoViricides in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons